These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19879533)

  • 21. Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy.
    Peterson PN; Daugherty SL; Wang Y; Vidaillet HJ; Heidenreich PA; Curtis JP; Masoudi FA;
    Circulation; 2009 Mar; 119(8):1078-84. PubMed ID: 19221223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Temporal Trends and Outcomes of Implantable Cardioverter Defibrillators in Heart Failure and Chronic Kidney Disease in the United States.
    Talha KM; Jain V; Yamani N; Fatima K; Rashid AM; Hernandez GA; Dani SS; Fudim M; Minhas AMK
    Curr Probl Cardiol; 2023 Apr; 48(4):101548. PubMed ID: 36566952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Outcomes in Patients with Severe Renal Dysfunction Including Dialysis Following Defibrillator Implantation.
    Bogdan S; Nof E; Eisen A; Sela R; Rosenheck S; Freedberg N; Geist M; Ben-Zvi S; Haim M; Glikson M; Goldenberg I; Suleiman M;
    Am J Nephrol; 2015; 42(4):295-304. PubMed ID: 26529418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States.
    Charytan DM; Patrick AR; Liu J; Setoguchi S; Herzog CA; Brookhart MA; Winkelmayer WC
    Am J Kidney Dis; 2011 Sep; 58(3):409-17. PubMed ID: 21664735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis.
    Schmitges J; Trinh QD; Sun M; Hansen J; Bianchi M; Jeldres C; Perrotte P; Dahlem R; Shariat SF; Chun FK; Montorsi F; Menon M; Fisch M; Graefen M; Karakiewicz PI
    BJU Int; 2012 Sep; 110(6 Pt B):E183-90. PubMed ID: 22321256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated B-type natriuretic peptide is associated with increased in-hospital mortality or cardiac arrest in patients undergoing implantable cardioverter-defibrillator implantation.
    Wei S; Loyo-Berríos NI; Haigney MC; Cheng H; Pinnow EE; Mitchell KR; Beachy JH; Woodward AM; Wang Y; Curtis JP; Marinac-Dabic D
    Circ Cardiovasc Qual Outcomes; 2011 May; 4(3):346-54. PubMed ID: 21487093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants: results from the National Cardiovascular Data Registry.
    Prutkin JM; Reynolds MR; Bao H; Curtis JP; Al-Khatib SM; Aggarwal S; Uslan DZ
    Circulation; 2014 Sep; 130(13):1037-43. PubMed ID: 25081281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased complication rates of cardiac rhythm management devices in ESRD patients.
    Dasgupta A; Montalvo J; Medendorp S; Lloyd-Jones DM; Ghossein C; Goldberger J; Passman R
    Am J Kidney Dis; 2007 May; 49(5):656-63. PubMed ID: 17472848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of implantable cardioverter defibrillators for primary prevention in the community: do women and men equally meet trial enrollment criteria?
    Daugherty SL; Peterson PN; Wang Y; Curtis JP; Heidenreich PA; Lindenfeld J; Vidaillet HJ; Masoudi FA;
    Am Heart J; 2009 Aug; 158(2):224-9. PubMed ID: 19619698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Advancing Age and Multiple Chronic Conditions on Mortality in Patients with End-Stage Renal Disease after Implantable Cardioverter-Defibrillator Placement.
    Krishnaswami A; Kiley ML; Anthony FF; Chen Y; Chen J; Rajagopal S; Liu TI; Young C; Paxton EW
    Perm J; 2016; 20(1):27-32. PubMed ID: 26562307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation.
    Tompkins C; Cheng A; Dalal D; Brinker JA; Leng CT; Marine JE; Nazarian S; Spragg DD; Sinha S; Halperin H; Tomaselli GF; Berger RD; Calkins H; Henrikson CA
    J Am Coll Cardiol; 2010 May; 55(21):2376-82. PubMed ID: 20488310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators.
    Herzog CA; Li S; Weinhandl ED; Strief JW; Collins AJ; Gilbertson DT
    Kidney Int; 2005 Aug; 68(2):818-25. PubMed ID: 16014061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of age on perioperative complications among patients undergoing implantable cardioverter-defibrillators for primary prevention in the United States.
    Tsai V; Goldstein MK; Hsia HH; Wang Y; Curtis J; Heidenreich PA;
    Circ Cardiovasc Qual Outcomes; 2011 Sep; 4(5):549-56. PubMed ID: 21878667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States.
    Friedman DJ; Parzynski CS; Varosy PD; Prutkin JM; Patton KK; Mithani A; Russo AM; Curtis JP; Al-Khatib SM
    JAMA Cardiol; 2016 Nov; 1(8):900-911. PubMed ID: 27603935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit.
    Parkash R; Sapp JL; Basta M; Doucette S; Thompson K; Gardner M; Gray C; Brownell B; Kidwai H; Cox J
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):706-13. PubMed ID: 22685111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombotic therapy and outcomes after ICD implantation in patients with atrial fibrillation and coronary artery disease: an analysis from the National Cardiovascular Data Registry (NCDR)®.
    Ghanbari H; Nallamothu BK; Wang Y; Curtis JP
    J Am Heart Assoc; 2015 Jan; 4(2):. PubMed ID: 25637345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current use of implantable electrical devices in Sweden: data from the Swedish pacemaker and implantable cardioverter-defibrillator registry.
    Gadler F; Valzania C; Linde C
    Europace; 2015 Jan; 17(1):69-77. PubMed ID: 25336667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A meta-analysis of mortality in end-stage renal disease patients receiving implantable cardioverter defibrillators (ICDs).
    Chen TH; Wo HT; Chang PC; Wang CC; Wen MS; Chou CC
    PLoS One; 2014; 9(7):e99418. PubMed ID: 25036181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.